guest ::
| Home > Publications database > Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study. > print |
| Home > Publications database > Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study. > print |
| 001 | 298230 | ||
| 005 | 20250518020535.0 | ||
| 024 | 7 | _ | |a 10.1002/ijc.35348 |2 doi |
| 024 | 7 | _ | |a pmid:39865612 |2 pmid |
| 024 | 7 | _ | |a 0020-7136 |2 ISSN |
| 024 | 7 | _ | |a 1097-0215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:173818450 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-00237 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Löfling, Leif Lukas |0 0000-0002-2731-8532 |b 0 |
| 245 | _ | _ | |a Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study. |
| 260 | _ | _ | |a Bognor Regis |c 2025 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1747037513_28858 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Jul 1;157(1):86-94 |
| 520 | _ | _ | |a Cancer diagnosis and therapy cause stress to the body. Preclinical studies have shown that stress hormones can stimulate tumor progression and metastasis by interacting with β-adrenergic receptors, and that β-blockers can inhibit those processes. We assessed if β-blocker use was associated with survival in a nationwide cohort of women with epithelial ovarian cancer (EOC). We identified all women aged ≥40 years who underwent EOC surgery in 2004-2018 in Norway through the Cancer Registry of Norway. We estimated the association between peri-diagnostic and post-diagnostic β-blocker use and survival. We used Cox models, adjusted for sociodemographic and health factors, and reported hazard ratios (HRs) and 95% confidence intervals (CIs). The difference in overall survival time between β-blocker users and non-users was estimated as the difference in restricted mean survival time at 5 years after diagnosis using flexible parametric models. We included 3911 women with EOC; 540 (14%) used β-blockers at diagnosis, 1672 (43%) died of the disease, and 1882 (48%) died overall. We found an association between peri-diagnostic β-blocker use and longer EOC-specific survival (HR = 0.85, 95%CI 0.73-1.00; p-value = 0.048), and an indication of an association with overall survival (HR = 0.89, 95%CI 0.77-1.02; p-value = 0.101). Analysis of post-diagnostic β-blocker use, which included only women who survived 12 months or longer (n = 3344), found similar associations. At 5 years from diagnosis, peri-diagnostic β-blocker users lived on average 1.28 months longer than non-users (95%CI 0.01-2.60 months). The results support the hypothesis that β-blocker use improves EOC-specific survival in women with EOC. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a beta‐blockers |2 Other |
| 650 | _ | 7 | |a ovarian cancer |2 Other |
| 650 | _ | 7 | |a population‐based |2 Other |
| 650 | _ | 7 | |a registry |2 Other |
| 650 | _ | 7 | |a survival |2 Other |
| 700 | 1 | _ | |a Støer, Nathalie C |b 1 |
| 700 | 1 | _ | |a Sloan, Erica K |b 2 |
| 700 | 1 | _ | |a Nafisi, Sara |0 0000-0003-3142-0596 |b 3 |
| 700 | 1 | _ | |a Fortner, Renée Turzanski |0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |b 4 |u dkfz |
| 700 | 1 | _ | |a Botteri, Edoardo |0 0000-0002-9023-8068 |b 5 |
| 773 | _ | _ | |a 10.1002/ijc.35348 |g p. ijc.35348 |0 PERI:(DE-600)1474822-8 |n 1 |p 86-94 |t International journal of cancer |v 157 |y 2025 |x 0020-7136 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:298230 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-17 |w ger |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2024-12-17 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-17 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-17 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2022 |d 2024-12-17 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2022 |d 2024-12-17 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|